CL2018001407A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents
Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncerInfo
- Publication number
- CL2018001407A1 CL2018001407A1 CL2018001407A CL2018001407A CL2018001407A1 CL 2018001407 A1 CL2018001407 A1 CL 2018001407A1 CL 2018001407 A CL2018001407 A CL 2018001407A CL 2018001407 A CL2018001407 A CL 2018001407A CL 2018001407 A1 CL2018001407 A1 CL 2018001407A1
- Authority
- CL
- Chile
- Prior art keywords
- ilo
- hydrogen
- metoxi
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
UN COMPUESTO DE FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE: Q PUEDE SER 1,2,4-TRIAZIN-3-ILO, PIRIDAZIN-3-ILO, 6-METILPIRIDAZIN-3-ILO, O 6-FLUOROPIRIDAZIN-3-ILO; R1 PUEDE SER HIDRÓGENO, METOXI, TRIFLUOROMETOXI, OXETAN-3-ILO, 3-FLUOROAZETIDIN-1-ILO, 3-METOXIAZETIDIN-1-ILO, O 3,3-DIFLUOROAZETIDIN-1-ILO; R2 PUEDE SER HIDRÓGENO O FLÚOR; R3 PUEDE SER HIDRÓGENO O METOXI; Y R4 PUEDE SER METOXI, ETOXI, O METOXIMETILO; CON LA CONDICIÓN DE QUE CUANDO R1 SEA HIDRÓGENO, METOXI O TRIFLUOROMETOXI, ENTONCES R3 NO SEA HIDRÓGENO, Y/O R4 ES METOXIMETILO. EL COMPUESTO DE FÓRMULA (I) PUEDE INHIBIR LA GLUTAMINASA, POR EJEMPLO, GLS1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562260789P | 2015-11-30 | 2015-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001407A1 true CL2018001407A1 (es) | 2018-10-12 |
Family
ID=57485461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001407A CL2018001407A1 (es) | 2015-11-30 | 2018-05-24 | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer |
Country Status (23)
Country | Link |
---|---|
US (3) | US10323028B2 (es) |
EP (1) | EP3383873B1 (es) |
JP (1) | JP6999550B2 (es) |
KR (1) | KR20180083942A (es) |
CN (1) | CN108349966B (es) |
AR (1) | AR106874A1 (es) |
AU (1) | AU2016363718B2 (es) |
BR (1) | BR112018010806A2 (es) |
CA (1) | CA3005495C (es) |
CL (1) | CL2018001407A1 (es) |
CO (1) | CO2018006928A2 (es) |
EA (1) | EA201891241A1 (es) |
ES (1) | ES2914333T3 (es) |
IL (1) | IL259510A (es) |
MX (1) | MX2018006532A (es) |
NI (1) | NI201800064A (es) |
PH (1) | PH12018501131A1 (es) |
RU (1) | RU2018123714A (es) |
SG (1) | SG11201803810XA (es) |
SV (1) | SV2018005702A (es) |
TN (1) | TN2018000127A1 (es) |
TW (1) | TW201733587A (es) |
WO (1) | WO2017093299A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
US9938265B2 (en) | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
US10323028B2 (en) | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
CN110741003B (zh) * | 2017-06-13 | 2021-07-23 | 南京明德新药研发有限公司 | 作为gls1抑制剂的化合物 |
AU2019363115B2 (en) | 2018-10-16 | 2021-12-09 | Medshine Discovery Inc. | Thiadiazole derivative and uses thereof as a GLS1 inhibitor |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
EA026656B1 (ru) | 2011-11-21 | 2017-05-31 | Калитера Байосайенсиз Инк. | Гетероциклические ингибиторы глютаминазы |
DK2920168T3 (da) * | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | Heterocykliske glutaminase-inhibitorer |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
DK3092236T3 (en) | 2014-01-06 | 2020-11-30 | Rhizen Pharmaceuticals S A | Nye glutaminaseinhibitorer |
EP3116872A4 (en) * | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
US10040789B2 (en) | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
US10323028B2 (en) | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 US US15/363,030 patent/US10323028B2/en active Active
- 2016-11-29 TW TW105139337A patent/TW201733587A/zh unknown
- 2016-11-30 TN TNP/2018/000127A patent/TN2018000127A1/en unknown
- 2016-11-30 EA EA201891241A patent/EA201891241A1/ru unknown
- 2016-11-30 KR KR1020187018472A patent/KR20180083942A/ko unknown
- 2016-11-30 WO PCT/EP2016/079250 patent/WO2017093299A1/en active Application Filing
- 2016-11-30 JP JP2018526716A patent/JP6999550B2/ja active Active
- 2016-11-30 ES ES16806028T patent/ES2914333T3/es active Active
- 2016-11-30 MX MX2018006532A patent/MX2018006532A/es unknown
- 2016-11-30 EP EP16806028.3A patent/EP3383873B1/en active Active
- 2016-11-30 BR BR112018010806A patent/BR112018010806A2/pt not_active Application Discontinuation
- 2016-11-30 CA CA3005495A patent/CA3005495C/en active Active
- 2016-11-30 SG SG11201803810XA patent/SG11201803810XA/en unknown
- 2016-11-30 AU AU2016363718A patent/AU2016363718B2/en active Active
- 2016-11-30 AR ARP160103663A patent/AR106874A1/es unknown
- 2016-11-30 CN CN201680067245.3A patent/CN108349966B/zh active Active
- 2016-11-30 RU RU2018123714A patent/RU2018123714A/ru not_active Application Discontinuation
-
2018
- 2018-05-22 IL IL259510A patent/IL259510A/en unknown
- 2018-05-24 CL CL2018001407A patent/CL2018001407A1/es unknown
- 2018-05-29 NI NI201800064A patent/NI201800064A/es unknown
- 2018-05-29 SV SV2018005702A patent/SV2018005702A/es unknown
- 2018-05-29 PH PH12018501131A patent/PH12018501131A1/en unknown
- 2018-06-29 CO CONC2018/0006928A patent/CO2018006928A2/es unknown
-
2019
- 2019-05-03 US US16/402,825 patent/US10981904B2/en active Active
-
2021
- 2021-04-15 US US17/231,164 patent/US11753405B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3005495C (en) | 2023-12-12 |
SV2018005702A (es) | 2018-11-27 |
AU2016363718B2 (en) | 2019-11-14 |
AR106874A1 (es) | 2018-02-28 |
WO2017093299A1 (en) | 2017-06-08 |
EA201891241A1 (ru) | 2019-01-31 |
EP3383873A1 (en) | 2018-10-10 |
TW201733587A (zh) | 2017-10-01 |
CA3005495A1 (en) | 2017-06-08 |
MX2018006532A (es) | 2019-05-15 |
US20170152255A1 (en) | 2017-06-01 |
CO2018006928A2 (es) | 2018-10-10 |
SG11201803810XA (en) | 2018-06-28 |
PH12018501131A1 (en) | 2019-01-21 |
KR20180083942A (ko) | 2018-07-23 |
US20210246131A1 (en) | 2021-08-12 |
AU2016363718A1 (en) | 2018-07-12 |
ES2914333T3 (es) | 2022-06-09 |
TN2018000127A1 (en) | 2019-10-04 |
US10981904B2 (en) | 2021-04-20 |
JP6999550B2 (ja) | 2022-02-10 |
CN108349966A (zh) | 2018-07-31 |
NI201800064A (es) | 2018-10-18 |
RU2018123714A (ru) | 2020-01-09 |
BR112018010806A2 (pt) | 2018-11-27 |
JP2018535986A (ja) | 2018-12-06 |
IL259510A (en) | 2018-07-31 |
US10323028B2 (en) | 2019-06-18 |
US20190389853A1 (en) | 2019-12-26 |
EP3383873B1 (en) | 2022-03-09 |
US11753405B2 (en) | 2023-09-12 |
CN108349966B (zh) | 2022-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
ECSP19042682A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CL2017000240A1 (es) | Compuestos activos hacia bromodominios | |
CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
BR112018075736A2 (pt) | composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1 | |
AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
SV2018005713A (es) | Compuestos de isoindol | |
CL2017001209A1 (es) | Inhibidor de cinasa aurora a | |
AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
CL2018001408A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
AR106849A1 (es) | Compuestos de bis-piridazina y su uso en el tratamiento del cáncer | |
CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
MX2020003554A (es) | Moduladores de la expresion de enac. | |
CY1125039T1 (el) | Νεα χρηση του ν,ν-δις-2-μερκαπτοαιθυλ ισοφθαλαμιδιου | |
AR107163A1 (es) | Inhibidores de quinasa | |
CL2022001353A1 (es) | Inhibidores de egfr | |
AR112813A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo | |
AR108363A1 (es) | Compuestos de tetrahidrofurooxazina y su uso como inhibidores de bace1 selectivos |